|
1
|
El-Serag HB: Hepatocellular Carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feitelson MA, Sun B, Tufan NL Satiroglu,
Liu J, Pan J and Lian Z: Genetic mechanisms of
hepatocarcinogenesis. Oncogene. 21:2593–2604. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, De Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR,
Bhagat N and Geschwind JF: Phase II trial of sorafenib combined
with concurrent transarterial chemoembolization with drug-eluting
beads for hepatocellular carcinoma. J Clin Oncol. 29:3960–3967.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Keating GM and Santoro A: Sorafenib: A
review of its use in advanced hepatocellular carcinoma. Drugs.
69:223–240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Belz G, Breithaupt-Grögler K and Osowski
U: Treatment of congestive heart failure-current status of use of
digitoxin. Eur J Clin Invest. 31 Suppl 2:10–17. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Elbaz HA, Stueckle TA, Tse W, Rojanasakul
Y and Dinu CZ: Digitoxin and its analogs as novel cancer
therapeutics. Exp Hematol Oncol. 1:42012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
López-Lázaro M: Digitoxin as an anticancer
agent with selectivity for cancer cells: Possible mechanisms
involved. Expert Opin Ther Targets. 11:1043–1053. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie JW, Chen PC, Zheng CH, Li P, Wang JB,
Lin JX, Lu J, Chen QY, Cao LL, Lin M, et al: Evaluation of the
prognostic value and functional roles of CD44v6 in gastric cancer.
J Cancer Res Clin Oncol. 141:1809–1817. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buck E, Eyzaguirre A, Brown E, Petti F,
McCormack S, Haley JD, Iwata KK, Gibson NW and Griffin G: Rapamycin
synergizes with the epidermal growth factor receptor inhibitor
erlotinib in non-small-cell lung, pancreatic, colon, and breast
tumors. Mol Cancer Ther. 5:2676–2684. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith TW: Digitalis toxicity: Epidemiology
and clinical use of serum concentration measurements. Am J Med.
58:470–476. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan G, Wang Q, Hu S, Wang D, Qiao Y, Ma G,
Tang C and Gu Y: Digoxin inhibits PDGF-BB-induced VSMC
proliferation and migration through an increase in ILK signaling
and attenuates neointima formation following carotid injury. Int J
Mol Med. 36:1001–1011. 2015.PubMed/NCBI
|
|
16
|
Lin SY, Chang HH, Lai YH, Lin CH, Chen MH,
Chang GC, Tsai MF and Chen JJ: Digoxin suppresses tumor malignancy
through inhibiting multiple Src-related signaling pathways in
non-small cell lung cancer. PLoS One. 10:e01233052015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ha TY, Hwang S, Moon KM, Won YJ, Song GW,
Kim N, Tak E, Ryoo BY and Hong HN: Sorafenib inhibits migration and
invasion of hepatocellular carcinoma cells through suppression of
matrix metalloproteinase expression. Anticancer Res. 35:1967–1976.
2015.PubMed/NCBI
|
|
18
|
Einbond LS, Shimizu M, Ma H, Wu HA,
Goldsberry S, Sicular S, Panjikaran M, Genovese G and Cruz E:
Actein inhibits the Na+-K+-ATPase and enhances the growth
inhibitory effect of digitoxin on human breast cancer cells.
Biochem Biophys Res Commun. 375:608–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Qian DZ, Tan YS, Lee K, Gao P,
Ren YR, Rey S, Hammers H, Chang D, Pili R, et al: Digoxin and other
cardiac glycosides inhibit HIF-1alpha synthesis and block tumor
growth. Proc Natl Acad Sci USA. 105:19579–19586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu M, Zheng YL, Xie XY, Liang JY, Pan FS,
Zheng SG and Lü MD: Sorafenib blocks the HIF-1α/VEGFA pathway,
inhibits tumor invasion and induces apoptosis in hepatoma cells.
DNA Cell Biol. 33:275–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pessetto ZY, Weir SJ, Sethi G, Broward MA
and Godwin AK: Drug repurposing for gastrointestinal stromal tumor.
Mol Cancer Ther. 12:1299–1309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Woodcock J and Woosley R: The FDA critical
path initiative and its influence on new drug development. Annu Rev
Med. 59:1–12. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roder C and Thomson MJ: Auranofin:
Repurposing an old drug for a golden new age. Drugs RD. 15:13–20.
2015. View Article : Google Scholar
|
|
24
|
Kourelis TV and Siegel RD: Metformin and
cancer: New applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Richards LG, Castle MC and Lage GL:
Glucuronidation of digitoxin and its derivatives by rat and rabbit
liver homogenates. Drug Metab Dispos. 5:469–473. 1977.PubMed/NCBI
|
|
26
|
Haux J: Digitoxin is a potential
anticancer agent for several types of cancer. Med Hypotheses.
53:543–548. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Elbaz HA, Stueckle TA, Wang HY, O'Doherty
GA, Lowry DT, Sargent LM, Wang L, Dinu CZ and Rojanasakul Y:
Digitoxin and a synthetic monosaccharide analog inhibit cell
viability in lung cancer cells. Toxicol Appl Pharmacol. 258:51–60.
2012. View Article : Google Scholar : PubMed/NCBI
|
